Cardiff Oncology, Inc(NASDAQ:CRDF) 
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has c...
Website: https://cardiffoncology.com/
Founded: 1999
Full Time Employees: 12
CEO: Mark Erlander
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2006-10-31 | 2006-07-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
royalty revenues | 243,000 | 120,000 | 121,000 | 109,000 | 151,000 | 165,000 | 163,000 | 205,000 | 156,000 | 141,000 | 108,000 | 83,000 | 128,000 | 93,000 | 91,000 | 74,000 | |||||||||||||||||||||||||||||||||||||||||||
costs and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
research and development | 5,075,000 | 8,197,000 | 11,580,000 | 10,477,000 | 9,712,000 | 9,640,000 | 9,493,000 | 8,008,000 | 7,763,000 | 8,022,000 | 8,020,000 | 9,052,000 | 6,442,000 | 6,009,000 | 7,448,000 | 7,208,000 | 5,824,000 | 4,154,000 | 4,119,000 | 3,279,000 | 3,199,171 | 2,854,812 | 2,475,722 | 2,705,691 | 2,864,473 | 2,818,824 | 2,830,340 | 2,648,599 | 2,496,965 | 1,830,441 | 1,952,767 | 1,883,838 | 1,206,399 | 1,414,706 | 981,715 | 4,279,830 | 3,784,766 | 3,937,398 | 4,076,414 | 3,208,064 | 3,165,520 | 2,546,533 | 2,684,157 | 2,197,659 | 1,834,961 | 1,990,251 | 1,397,173 | 1,442,521 | 1,286,038 | 915,457 | 943,849 | 802,245 | 594,101 | 511,433 | 477,151 | 337,407 | |||
selling, general and administrative | 2,995,000 | 3,897,000 | 3,318,000 | 4,014,000 | 3,011,000 | 3,126,000 | 3,215,000 | 3,130,000 | 2,725,000 | 2,939,000 | 4,296,000 | 3,083,000 | 3,078,000 | 3,077,000 | 3,086,000 | 3,940,000 | 3,835,000 | 2,930,000 | 2,838,000 | 2,235,000 | 3,417,014 | 1,644,211 | 1,669,227 | 1,486,019 | 1,517,400 | 1,440,339 | 1,527,904 | 1,475,122 | 1,684,535 | 1,665,200 | 2,150,871 | 2,504,977 | |||||||||||||||||||||||||||
total operating expenses | 8,070,000 | 12,094,000 | 14,898,000 | 14,491,000 | 12,723,000 | 12,766,000 | 12,708,000 | 11,138,000 | 10,488,000 | 10,961,000 | 12,316,000 | 12,135,000 | 9,520,000 | 9,086,000 | 10,534,000 | 11,148,000 | 9,659,000 | 7,084,000 | 6,957,000 | 5,514,000 | 6,616,185 | 4,499,023 | 4,144,949 | 4,191,710 | 4,381,873 | 4,259,163 | 4,358,244 | 4,123,721 | 4,181,500 | 3,943,669 | 4,551,409 | 4,755,159 | 3,969,303 | 5,920,950 | 5,990,264 | 10,220,684 | 9,850,303 | 10,013,601 | 10,083,645 | 10,579,134 | 7,463,310 | 6,466,879 | 6,681,553 | 4,974,722 | 4,560,094 | 3,997,427 | 3,297,226 | 3,370,591 | 2,896,304 | 3,121,409 | 2,423,112 | 2,508,962 | 1,597,697 | 1,250,475 | 1,287,019 | 1,164,371 | -2,219,576 | 1,559,633 | 1,953,165 |
income from operations | -7,827,000 | -11,974,000 | -14,777,000 | -14,382,000 | -12,572,000 | -12,601,000 | -12,545,000 | -10,933,000 | -10,332,000 | -10,820,000 | -12,208,000 | -12,052,000 | -9,392,000 | -8,993,000 | -10,443,000 | -11,074,000 | -9,526,000 | -6,998,000 | -6,889,000 | -5,442,000 | -6,496,930 | -4,362,622 | -4,102,316 | -4,124,006 | -4,289,296 | -4,207,476 | -4,219,959 | -3,961,763 | -4,103,485 | -3,855,308 | -4,439,596 | -4,655,023 | -3,784,277 | -5,797,621 | -5,888,253 | -10,125,646 | -9,782,231 | -9,924,487 | -9,980,245 | -10,458,648 | -7,384,141 | -6,409,552 | |||||||||||||||||
yoy | -37.74% | -4.98% | 17.79% | 31.55% | 21.68% | 16.46% | 2.76% | -9.28% | 10.01% | 20.32% | 16.90% | 8.83% | -1.41% | 28.51% | 51.59% | 103.49% | 46.62% | 60.41% | 67.93% | 31.96% | 51.47% | 3.69% | -2.79% | 4.10% | 4.53% | 9.13% | -4.95% | -14.89% | 8.44% | -33.50% | -24.60% | -54.03% | -61.31% | -41.58% | -41.00% | -3.18% | 32.48% | 54.84% | |||||||||||||||||||||
qoq | -34.63% | -18.97% | 2.75% | 14.40% | -0.23% | 0.45% | 14.74% | 5.82% | -4.51% | -11.37% | 1.29% | 28.32% | 4.44% | -13.88% | -5.70% | 16.25% | 36.12% | 1.58% | 26.59% | -16.24% | 48.92% | 6.35% | -0.53% | -3.85% | 1.94% | -0.30% | 6.52% | -3.45% | 6.44% | -13.16% | -4.63% | 23.01% | -34.73% | -1.54% | -41.85% | 3.51% | -1.43% | -0.56% | -4.57% | 41.64% | 15.21% | ||||||||||||||||||
operating margin % | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -16860.18% | -8137.21% | -10130.88% | -7558.33% | -5447.93% | -3198.38% | -9622.40% | -6091.23% | -4633.22% | -8140.30% | -3051.64% | -2446.17% | -5259.87% | -4363.13% | -3970.55% | -4648.70% | -2045.27% | -4700.94% | -5772.17% | -10654.31% | -14370.42% | -11136.84% | -9652.07% | -8680.38% | -9327.06% | -11180.69% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | NaN% | NaN% | NaN% |
other income, net: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income | 612,000 | 716,000 | 835,000 | 941,000 | 787,000 | 741,000 | 805,000 | 926,000 | 1,008,000 | 1,068,000 | 1,053,000 | 940,000 | 740,000 | 458,000 | 253,000 | 130,000 | 79,000 | 70,000 | 71,000 | 57,000 | 22,451 | 15,864 | 15,671 | 35,823 | 45,965 | 53,700 | 69,761 | 64,743 | 75,519 | 85,938 | 24,273 | 17,368 | 9,251 | 6,369 | 4,299 | 3,470 | 2,079 | 2,391 | 3,619 | 44 | |||||||||||||||||||
other income | -1,000 | -1,000 | 7,000 | -9,250 | 5,000 | -38,000 | -4,000 | -21,250 | 21,000 | 5,000 | -111,000 | -45,000 | -36,000 | -253,000 | -49,000 | 3,750 | 3,000 | -1,000 | -491.75 | -5,738 | 6,257 | -2,486 | 503 | -1,103 | 1,106 | 2,010 | -17,130.25 | 2,318 | -71,839 | 1,000 | 1,566 | 9,179 | 6,211.25 | 15,688.75 | 15,035 | 22,751 | |||||||||||||||||||||||
total other income | 611,000 | 716,000 | 834,000 | 948,000 | 785,000 | 746,000 | 767,000 | 922,000 | 995,000 | 1,089,000 | 1,058,000 | 829,000 | 695,000 | 422,000 | 81,000 | ||||||||||||||||||||||||||||||||||||||||||||
net income | -7,216,000 | -11,258,000 | -13,943,000 | -13,434,000 | -11,787,000 | -11,855,000 | -11,778,000 | -10,011,000 | -9,337,000 | -9,731,000 | -11,150,000 | -11,223,000 | -8,697,000 | -8,571,000 | -10,443,000 | -10,993,000 | -9,442,000 | -6,913,000 | -6,757,000 | -5,179,000 | -6,597,047 | -4,496,531 | -4,124,532 | -4,088,562 | -4,242,536 | -4,141,549 | -4,125,303 | -3,904,771 | -4,158,478 | -3,769,568 | -3,746,955 | -4,786,177 | -2,569,430 | -4,291,966 | -8,045,811 | -9,999,537 | -8,547,651 | -10,191,272 | -10,262,518 | -0.105 | -0.05 | -0.28 | |||||||||||||||||
yoy | -38.78% | -5.04% | 18.38% | 34.19% | 26.24% | 21.83% | 5.63% | -10.80% | 7.36% | 13.53% | 6.77% | 2.09% | -7.89% | 23.98% | 54.55% | 112.26% | 43.12% | 53.74% | 63.82% | 26.67% | 55.50% | 8.57% | -0.02% | 4.71% | 2.02% | 9.87% | 10.10% | -18.42% | 61.84% | -12.17% | -53.43% | -52.14% | -69.94% | -57.89% | -2.56% | ||||||||||||||||||||||||
qoq | -35.90% | -19.26% | 3.79% | 13.97% | -0.57% | 0.65% | 17.65% | 7.22% | -4.05% | -12.73% | -0.65% | 29.04% | 1.47% | -17.93% | -5.00% | 16.43% | 36.58% | 2.31% | 30.47% | -21.50% | 46.71% | 9.02% | 0.88% | -3.63% | 2.44% | 0.39% | 5.65% | -6.10% | 10.32% | 0.60% | -21.71% | 86.27% | -40.13% | -46.66% | -19.54% | 16.99% | -16.13% | 110.00% | -82.14% | ||||||||||||||||||||
net income margin % | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -16711.50% | -8038.37% | -9936.76% | -7193.06% | -5531.88% | -3296.55% | -9674.51% | -6038.88% | -4582.71% | -8012.75% | -2983.19% | -2410.98% | -5330.36% | -4266.10% | -3351.09% | -4779.68% | -1388.69% | -3480.09% | -7887.20% | -10521.62% | -12556.78% | -11436.22% | 0% | -8517.60% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.00% | -0.00% | -0.00% | 0% | NaN% | NaN% | NaN% |
preferred stock dividend payable on series a convertible preferred stock | -7,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,000 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | ||||||||||||||||||||||||||||
net loss attributable to common stockholders | -7,223,000 | -11,264,000 | -13,949,000 | -13,440,000 | -11,793,000 | -11,861,000 | -11,784,000 | -10,017,000 | -9,343,000 | -9,737,000 | -11,156,000 | -11,229,000 | -8,703,000 | -8,577,000 | -10,449,000 | -10,999,000 | -9,448,000 | -6,919,000 | -6,763,000 | -5,185,000 | -6,603,107 | -4,502,591 | -7,397,076 | -4,094,622 | -4,248,596 | -4,147,609 | -4,131,363 | -4,179,100 | -4,164,538 | -3,775,628 | -6,522,548 | -4,792,237 | -2,575,490 | -4,298,026 | -8,051,871 | -10,005,597 | -8,553,711 | -10,197,332 | -10,268,578 | -2,414,765 | -5,381,277 | -1,078,776 | -3,199,006 | ||||||||||||||||
net loss per common share — basic and diluted | -110 | -170 | -210 | -200 | -210 | -250 | -260 | -220 | -210 | -220 | -250 | -250 | -200 | -200 | -240 | -250 | -240 | -170 | -170 | -140 | -0.08 | -0.19 | -0.51 | -0.41 | |||||||||||||||||||||||||||||||||||
weighted-average shares outstanding — basic and diluted | 66,841,000 | 66,879,000 | 66,526,000 | 66,524,000 | 47,650,000 | 46,865,000 | 44,825,000 | 44,678,000 | 44,677,000 | 44,677,000 | 44,677,000 | 44,677,000 | 43,600,000 | 43,333,000 | 43,306,000 | 43,231,000 | 39,030,000 | 39,552,000 | 38,761,000 | 37,164,000 | 20,874,665 | 23,341,218 | 14,492,159 | 9,910,306 | 5,973,906 | ||||||||||||||||||||||||||||||||||
gain from change in fair value of derivative financial instruments—warrants | 70,000 | 12,000 | 61,000 | 207,000 | -46,518 | -144,035 | -44,144 | 2,107 | 6,839.75 | 13,330 | 23,789 | 144,760 | -2,500 | 711,229 | -129,689 | 503,186.75 | 1,528,669 | -71,428 | 555,506 | ||||||||||||||||||||||||||||||||||||||||
revenues: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
royalties | 56,500 | 86,000 | 68,000 | 72,000 | 119,255 | 136,401 | 42,633 | 67,704 | 92,577 | 51,687 | 36,852 | 62,021 | 76,407 | 72,568 | 52,423 | 49,055 | 116,029 | 58,779 | 44,810 | 65,826 | 50,193 | 47,236 | 47,765 | ||||||||||||||||||||||||||||||||||||
total revenues | 56,500 | 86,000 | 68,000 | 72,000 | 119,255 | 136,401 | 42,633 | 67,704 | 92,577 | 51,687 | 138,285 | 161,958 | 78,015 | 88,361 | 111,813 | 100,136 | 185,026 | 123,329 | 102,011 | 95,038 | 68,072 | 89,114 | 103,400 | 120,486 | 79,169 | 57,327 | 49,346 | 126,970 | 56,398 | 57,199 | 55,628 | 110,953 | 47,367 | 43,756 | 49,000 | 119,123 | 163,251 | 211,500 | 41,500 | 34,153 | |||||||||||||||||||
yoy | -52.62% | -36.95% | 59.50% | 6.35% | 28.82% | 163.90% | -69.17% | -58.20% | 18.67% | -41.50% | 23.68% | 61.74% | -57.84% | -28.35% | 9.61% | 5.36% | 171.81% | 38.39% | -1.34% | -21.12% | -14.02% | 55.45% | 109.54% | -5.11% | 40.38% | 0.22% | -11.29% | 14.44% | 19.07% | 30.72% | 13.53% | -6.86% | -70.99% | -79.31% | 18.07% | 248.79% | |||||||||||||||||||||||
qoq | -34.30% | 26.47% | -5.56% | -39.63% | -12.57% | 219.94% | -37.03% | -26.87% | 79.11% | -62.62% | -14.62% | 107.60% | -11.71% | -20.97% | 11.66% | -45.88% | 50.03% | 20.90% | 7.34% | 39.61% | -23.61% | -13.82% | -14.18% | 52.19% | 38.10% | 16.17% | -61.14% | 125.13% | -1.40% | 2.82% | -49.86% | 134.24% | 8.25% | -10.70% | -58.87% | -27.03% | -22.81% | 409.64% | 21.51% | ||||||||||||||||||||
deemed dividend recognized on beneficial conversion features of series d convertible preferred stock issuance | -601,767 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized on beneficial conversion features of series e convertible preferred stock issuance | -2,664,717 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
services | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized on beneficial conversion features of series c convertible preferred stock issuance | -268,269 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
services and other | 373.75 | 101,433 | 99,937 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of revenues | 149,364.25 | 26,677 | 204,436 | 366,344 | 356,957.75 | 473,202 | 338,203 | 616,426 | 285,823.25 | 424,559 | 409,463 | ||||||||||||||||||||||||||||||||||||||||||||||||
restructuring charges | 421,351 | 243,335 | 1,719,804 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense | -232 | -16 | -392,414 | -352,727 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | 17,974 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized on beneficial conversion features of series b convertible preferred stock issuance | -2,769,533 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share — basic | -0.615 | -0.71 | -0.79 | -1.02 | -6.88 | -0.18 | -0.88 | -0.09 | -0.04 | -0.12 | -0.26 | -0.32 | -0.28 | -0.34 | -0.34 | -0.35 | -0.25 | -0.1 | -0.41 | ||||||||||||||||||||||||||||||||||||||||
net loss per common share — diluted | -0.615 | -0.71 | -0.79 | -1.02 | -6.88 | -0.18 | -0.88 | -0.09 | -0.04 | -0.12 | -0.26 | -0.32 | -0.33 | -0.34 | -0.34 | -0.36 | -0.25 | -0.23 | -0.41 | ||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding — basic | 5,822,818 | 5,241,924 | 4,086,561 | 2,330,180 | 20,622,660 | 7,423,463 | 55,364,438 | 34,680,362 | 36,465,672 | 30,991,740 | 30,961,014 | 30,174,838 | 30,339,774 | 29,958,037 | 29,755,184 | 26,201,713 | 28,560,211 | 24,592,883 | |||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding — diluted | 5,822,818 | 5,241,924 | 4,086,561 | 2,330,180 | 20,622,660 | 7,423,463 | 55,364,438 | 34,680,362 | 36,465,672 | 30,991,740 | 30,961,014 | 30,281,263 | 30,339,774 | 29,958,037 | 30,108,377 | 26,452,165 | 29,128,235 | ||||||||||||||||||||||||||||||||||||||||||
loss from change in fair value of derivative financial instruments—warrants | -9,761 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diagnostic services | 20,912.5 | 4,303 | 39,345 | 40,002 | 53,629 | 58,119 | 55,501 | 28,862 | 16,579 | 37,978 | 23,962 | ||||||||||||||||||||||||||||||||||||||||||||||||
clinical research services | 10,653.5 | 11,490 | 20,045 | 15,368 | 6,431 | 1,700 | 350 | 1,300 | 3,900 | 31,673 | |||||||||||||||||||||||||||||||||||||||||||||||||
net interest income | 35,277 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
clinical research | 11,079 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net interest expense | -2,465 | -219,435.25 | -16,473 | -431,871 | -429,397 | -407,990 | -354,993 | -274,909 | -337,620 | ||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock dividend | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | -6,060 | ||||||||||||||||||||||||||||||||||||||||||||||||
selling and marketing | 292,479 | 419,927 | 615,019 | 1,407,985 | 2,395,694 | 2,940,862 | 3,129,036 | 3,057,552 | 1,934,812 | 1,798,263 | 1,915,850 | 794,653 | 1,034,915 | 540,584 | 589,814 | 569,590 | |||||||||||||||||||||||||||||||||||||||||||
general and administrative | 1,582,107 | 3,659,587 | 4,059,133 | 2,196,639 | 2,292,186 | 2,710,782 | 2,468,732 | 4,004,247 | 2,163,779 | 1,948,546 | 2,001,516 | 1,805,985 | 1,674,777 | 1,466,592 | 1,310,239 | 1,358,480 | 1,347,983 | 2,205,952 | 1,479,263 | 1,706,717 | 1,003,596 | 739,042 | 809,868 | 826,964 | |||||||||||||||||||||||||||||||||||
restructuring (benefit) charges | 417,381.5 | -46,472 | -3,806 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | -1,655,825 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other loss | -165,163 | -6,541 | 1,154.25 | -8,130 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain from change in fair value of derivative financial instruments — warrants | 168,708.5 | 88,208 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain from change in fair value of derivative instruments — warrants | 52,876 | 533,750 | -276,317.5 | 4,017,212 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss and comprehensive loss | -10,202,278 | -7,380,850 | -2,735,829 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss and comprehensive loss attributable to common stockholders | -10,208,338 | -7,386,910 | -2,741,889 | -10,186,094 | -7,180,441 | -1,116,581 | -6,336,246 | -659,785 | -1,172,202 | ||||||||||||||||||||||||||||||||||||||||||||||||||
royalty income | 112,868 | 51,717 | 51,301 | 46,826 | 124,804 | 56,398 | 57,199 | 45,628 | 110,953 | 47,367 | 43,756 | 49,000 | 119,123 | 58,251 | 41,500 | 41,500 | 34,153 | ||||||||||||||||||||||||||||||||||||||||||
diagnostic service revenue | 7,618 | 3,077 | 6,026 | 2,520 | 2,166 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of revenue | 309,271 | 199,199 | 173,537 | 80,030 | 176,425 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
license fees | 10,000 | 105,000 | 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding —diluted | 24,592,883 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of equipment | 3,568 | 44,101 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain from change in fair value of derivative instruments—warrants | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share - basic and diluted | -0.33 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding - basic and diluted | 21,817,710 | 18,902,782 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative instruments—warrants | 305,163.75 | 2,217,142 | 388,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share-basic and diluted | -0.128 | -0.28 | -0.06 | -0.17 | -0.04 | -0.25 | -0.34 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding- basic and diluted | 18,902,783 | 18,902,782 | 17,870,703 | 15,583,957 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
milestone fees | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchased in-process research and development — related party | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred debt costs and original issue discount | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative instruments-warrants | 32,846 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liquidated damages and other forbearance agreement settlement costs | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative effect of early adopting asc topic 815-40 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock conversion rate change accreted as a dividend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchased in process research and development | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of equipment | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss and comprehensive loss available to common stockholders | -2,700,662 | -4,406,592 | -5,279,475 | -3,435,970 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchased in-process research and development expense-related party | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating income | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative instruments | 1,279,143 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative effect of early adoption of asc 815-40 on november 1, 2006 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
series a convertible preferred stock beneficial conversion feature accreted as a dividend | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares of common stock outstanding: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 15,510,340 | 66,010,076 | 58,269,113 | 19,263,879 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | -0.07 | -0.02 | -0.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income and comprehensive income | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss per common share-basic and diluted: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted-average shares outstanding: | 14,178,733 | 12,086,528 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
revenues | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
research and development: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash stock-based compensation | 44,176.75 | 70,807 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other | 614,766 | 694,967 | 950,267 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total | 658,942.75 | 765,774 | 1,022,404 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of costs associated with abandoned leasehold improvement project | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative financial instruments | 73,482.25 | 34,660 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total other expense | 48,228.25 | 242,350 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
items attributed to preferred stock: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accretion on series a preferred stock | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss attributable to common shareholders | -1,330,125.75 | -1,656,620 | -1,729,192 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
weighted average shares of common stock outstanding: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic and diluted | 20,015,612 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash charge for stock-based compensation | 72,137 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative financial instrument - income | 219,599 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2015-12-31 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2006-10-31 | 2006-07-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 17,470,000 | 10,135,000 | 10,784,000 | 24,095,000 | 51,470,000 | 13,038,000 | 25,501,000 | 18,658,000 | 21,655,000 | 15,233,000 | 19,369,000 | 15,017,000 | 16,347,000 | 18,717,000 | 20,965,000 | 20,052,000 | 11,943,000 | 13,165,000 | 10,581,000 | 14,662,000 | 130,980,681 | 36,405,432 | 27,754,813 | 9,277,025 | 10,195,292 | 9,032,206 | 10,791,270 | 11,330,079 | 11,453,133 | 15,065,913 | 18,485,950 | 6,657,158 | 8,225,764 | 7,434,298 | 7,783,891 | 10,183,460 | 13,915,094 | 22,569,107 | 22,578,980 | 67,493,047 | 41,293,784 | 43,995,642 | 27,293,798 | 31,163,559 | 34,673,893 | 22,871,122 | 25,836,937 | 27,799,387 | 9,164,275 | 10,819,781 | 7,815,128 | 9,304,410 | ||
short-term investments | 40,834,000 | 50,456,000 | 60,173,000 | 55,792,000 | 40,276,000 | 44,629,000 | 34,818,000 | 48,529,000 | 53,168,000 | 66,130,000 | 70,059,000 | 81,951,000 | 88,920,000 | 95,586,000 | 101,041,000 | 109,310,000 | 128,878,000 | 120,882,000 | 129,470,000 | 110,922,000 | 18,619,712 | 23,978,022 | 24,376,904 | 28,004,561 | ||||||||||||||||||||||||||||||
accounts receivable and unbilled receivable | 182,000 | 254,000 | 526,000 | 405,000 | 773,000 | 618,000 | 451,000 | 393,000 | 288,000 | 198,000 | 161,000 | 676,000 | 771,000 | 650,000 | 551,000 | 447,000 | 535,000 | 395,000 | 308,000 | 242,000 | 320,458 | 204,366 | 109,334 | 106,432 | 203,480 | 152,038 | 122,281 | 115,676 | 167,755 | 128,577 | 124,082 | 114,343 | ||||||||||||||||||||||
prepaid expenses and other current assets | 1,642,000 | 956,000 | 2,213,000 | 2,419,000 | 2,535,000 | 1,047,000 | 1,476,000 | 2,410,000 | 2,301,000 | 2,344,000 | 3,142,000 | 4,109,000 | 5,246,000 | 4,802,000 | 4,857,000 | 5,997,000 | 4,771,000 | 3,327,000 | 2,512,000 | 2,744,000 | 1,578,859 | 954,986 | 899,451 | 849,082 | 1,001,840 | 1,068,144 | 1,165,828 | 939,200 | 33,649 | |||||||||||||||||||||||||
total current assets | 60,128,000 | 61,801,000 | 73,696,000 | 82,711,000 | 95,054,000 | 59,332,000 | 62,246,000 | 69,990,000 | 77,412,000 | 83,905,000 | 92,731,000 | 101,753,000 | 111,284,000 | 119,755,000 | 127,414,000 | 135,806,000 | 146,127,000 | 137,769,000 | 142,871,000 | 128,570,000 | 133,356,460 | 38,188,657 | 28,819,133 | 10,282,908 | 11,353,729 | 9,976,784 | 11,820,017 | 12,336,480 | 12,765,265 | 16,043,572 | 19,643,372 | 7,839,645 | 9,468,687 | 8,551,625 | 8,655,249 | 29,729,365 | 38,950,192 | 47,977,551 | 51,619,931 | 68,381,068 | 41,901,909 | 44,473,073 | 27,719,751 | 31,573,947 | 35,029,558 | 23,262,613 | 26,068,720 | 27,998,346 | 9,349,423 | 11,048,203 | 8,000,568 | 9,440,175 | 492,249 | 1,719,225 |
property and equipment | 578,000 | 666,000 | 743,000 | 805,000 | 898,000 | 993,000 | 1,095,000 | 1,199,000 | 1,238,000 | 1,317,000 | 1,356,000 | 1,320,000 | 1,269,000 | 1,304,000 | 1,138,000 | 550,000 | 382,000 | 383,000 | 422,000 | 504,000 | 623,694 | 682,859 | 655,367 | 758,503 | 877,823 | 271,401 | 252,053 | 293,361 | 1,304,433 | 1,627,605 | 1,803,921 | 2,223,597 | 2,426,312 | 3,126,969 | 3,321,532 | 3,567,064 | 3,826,915 | 4,654,876 | 4,731,738 | 2,690,579 | 1,378,941 | 1,022,534 | 840,387 | 841,434 | 817,024 | 859,645 | 750,565 | 740,307 | 330,314 | 254,742 | 208,393 | 149,498 | 96,990 | 230,068 |
operating lease right-of-use assets | 629,000 | 764,000 | 899,000 | 1,034,000 | 1,169,000 | 1,304,000 | 1,439,000 | 1,574,000 | 1,708,000 | 1,843,000 | 1,978,000 | 2,115,000 | 2,251,000 | 2,388,000 | 2,524,000 | 2,660,000 | 2,796,000 | 3,017,000 | 178,000 | 261,000 | 343,001 | 423,163 | 501,894 | 617,622 | 697,418 | 1,503,335 | 1,660,631 | 1,816,286 | ||||||||||||||||||||||||||
other assets | 549,000 | 549,000 | 401,000 | 257,000 | 69,000 | 1,267,000 | 1,271,000 | 1,275,000 | 1,279,000 | 1,387,000 | 1,390,000 | 1,361,000 | 1,387,000 | 184,000 | 185,000 | 188,000 | 239,000 | 143,000 | 263,000 | 238,000 | 404,232 | 155,770 | 152,585 | 156,370 | 157,576 | 170,943 | 135,262 | 87,073 | 102,798 | 249,645 | 320,749 | 345,277 | 389,942 | 539,309 | 583,973 | 628,640 | 1,173,304 | 371,243 | 371,243 | 374,004 | 362,946 | 336,708 | 336,708 | 346,902 | 346,902 | 336,450 | 336,450 | 411,912 | 518,775 | 362,081 | 362,081 | 362,081 | ||
total assets | 61,884,000 | 63,780,000 | 75,739,000 | 84,807,000 | 97,190,000 | 62,896,000 | 66,051,000 | 74,038,000 | 81,637,000 | 88,452,000 | 97,455,000 | 106,549,000 | 116,191,000 | 123,631,000 | 131,261,000 | 139,204,000 | 149,544,000 | 141,312,000 | 143,734,000 | 129,573,000 | 134,727,387 | 39,450,449 | 30,128,979 | 11,815,403 | 13,086,546 | 11,922,463 | 13,867,963 | 14,533,200 | 14,172,496 | 17,920,822 | 21,768,042 | 10,408,519 | 12,284,941 | 12,217,903 | 12,560,754 | 33,925,069 | 43,950,411 | 53,003,670 | 56,722,912 | 71,445,651 | 43,643,796 | 45,832,315 | 28,896,846 | 32,762,283 | 36,193,484 | 24,458,708 | 27,155,735 | 29,150,565 | 10,198,512 | 11,665,026 | 8,571,042 | 9,951,754 | 644,937 | 2,004,991 |
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 8,087,000 | 2,441,000 | 6,010,000 | 3,629,000 | 4,821,000 | 4,643,000 | 5,108,000 | 5,191,000 | 1,966,000 | 2,179,000 | 2,939,000 | 2,914,000 | 1,956,000 | 1,425,000 | 1,522,000 | 1,261,000 | 1,439,000 | 396,000 | 543,000 | 803,000 | 1,366,008 | 610,236 | 1,155,531 | 598,985 | 656,304 | 492,367 | 525,690 | 466,747 | 664,840 | 476,300 | 565,413 | 651,671 | 825,244 | 675,499 | 602,738 | 968,385 | 1,130,536 | 925,173 | 1,115,340 | 1,040,868 | 1,110,749 | 484,709 | 747,799 | 461,769 | 379,715 | 427,424 | 286,608 | 158,982 | 323,366 | 175,679 | 140,034 | 530,785 | ||
accrued liabilities | 7,577,000 | 11,539,000 | 9,938,000 | 8,946,000 | 7,897,000 | 7,175,000 | 6,712,000 | 5,956,000 | 7,783,000 | 6,151,000 | 5,501,000 | 4,555,000 | 5,177,000 | 6,138,000 | 6,279,000 | 4,738,000 | 4,527,000 | 3,850,763 | 3,260,061 | 1,813,842 | 1,454,587 | 4,021,365 | ||||||||||||||||||||||||||||||||
operating lease liabilities | 730,000 | 726,000 | 721,000 | 716,000 | 710,000 | 707,000 | 702,000 | 696,000 | 691,000 | 688,000 | 683,000 | 679,000 | 675,000 | 674,000 | 670,000 | 665,000 | 551,000 | 594,000 | 402,000 | 635,000 | 860,206 | 883,534 | 877,607 | 870,592 | 865,379 | 836,294 | 816,102 | 796,246 | ||||||||||||||||||||||||||
total current liabilities | 16,394,000 | 14,706,000 | 16,669,000 | 13,291,000 | 13,428,000 | 12,525,000 | 12,522,000 | 11,843,000 | 10,440,000 | 9,018,000 | 9,123,000 | 8,148,000 | 7,808,000 | 8,245,000 | 8,481,000 | 6,664,000 | 6,559,000 | 5,042,000 | 4,579,000 | 4,479,000 | 6,118,977 | 5,442,070 | 4,962,029 | 4,881,300 | 4,781,744 | 4,170,814 | 3,694,057 | 3,284,730 | 2,965,318 | 2,666,611 | 3,218,344 | 3,853,762 | 3,945,770 | 5,082,003 | 7,462,182 | 8,957,810 | 7,797,256 | 6,564,716 | 10,889,089 | 8,201,097 | 4,950,045 | 5,305,246 | 4,488,155 | 3,122,433 | 1,979,400 | 2,032,064 | 2,008,866 | 1,360,696 | 1,176,360 | 730,370 | 757,543 | 1,235,595 | ||
operating lease liabilities, net of current portion | 102,000 | 284,000 | 464,000 | 640,000 | 813,000 | 979,000 | 1,141,000 | 1,301,000 | 1,458,000 | 1,607,000 | 1,753,000 | 1,898,000 | 2,040,000 | 2,174,000 | 2,306,000 | 2,438,000 | 2,568,000 | 2,691,000 | 6,000 | 8,000 | 9,291 | 207,178 | 429,776 | 649,621 | 860,963 | 1,090,713 | 1,307,384 | 1,520,213 | ||||||||||||||||||||||||||
total liabilities | 16,496,000 | 14,990,000 | 17,133,000 | 13,931,000 | 14,241,000 | 13,504,000 | 13,663,000 | 13,144,000 | 11,898,000 | 10,625,000 | 10,876,000 | 10,046,000 | 9,848,000 | 10,419,000 | 10,787,000 | 9,102,000 | 9,127,000 | 7,768,000 | 4,816,000 | 4,756,000 | 6,569,505 | 5,927,899 | 5,744,940 | 5,671,985 | 5,775,202 | 5,266,483 | 5,019,728 | 4,847,019 | 4,088,304 | 3,941,067 | 4,290,880 | 5,729,429 | 5,778,834 | 8,273,031 | 9,049,985 | 23,244,581 | 24,182,272 | 26,229,271 | 24,150,038 | 22,744,362 | 25,524,856 | 22,269,640 | 20,547,293 | 20,408,527 | 18,864,149 | 6,705,941 | 6,763,735 | 8,012,411 | 8,662,845 | 9,495,998 | 3,595,650 | 4,462,453 | 508,158 | 493,515 |
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value... | 1,000 | 716 | 60 | 60 | 60 | 60 | 260 | 60 | 60 | 66 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 60 | 78 | 96 | 96 | 96 | 1,058,152 | 1,072,456 | |||||||||||||||||||||
common stock, 0.0001 par value... | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,678 | 10,081 | 9,585 | 8,554 | 8,312 | 8,096 | 7,997 | 7,906 | 7,742 | 7,738 | 7,173 | 5,883 | 5,279 | 3,811 | 3,108 | 3,098 | 3,070 | 3,060 | 3,015 | 2,974 | 2,487 | 2,431 | 1,891 | 1,890 | 1,890 | 1,890 | 1,890 | 1,889 | 1,551 | 1,547 | 1,418 | 1,418 | 2,003 | 1,990 |
additional paid-in capital | 475,361,000 | 471,547,000 | 470,138,000 | 468,455,000 | 467,087,000 | 421,697,000 | 413,017,000 | 409,781,000 | 409,343,000 | 408,434,000 | 407,479,000 | 405,898,000 | 404,834,000 | 403,822,000 | 402,710,000 | 401,655,000 | 400,503,000 | 384,551,000 | 383,611,000 | 363,350,000 | 361,820,025 | 260,807,295 | 247,528,273 | 219,805,965 | 217,172,528 | 212,463,077 | 210,706,090 | 207,652,843 | 202,267,605 | 201,998,634 | 201,720,972 | 182,401,648 | 179,546,954 | 174,426,891 | 169,693,921 | 168,811,755 | 167,890,984 | 166,337,512 | 161,930,622 | 157,585,498 | 116,874,837 | 112,132,535 | 89,739,511 | 89,054,276 | 88,648,577 | 87,993,233 | 87,433,460 | 87,141,485 | 57,853,251 | 57,370,017 | 53,840,264 | 53,694,388 | 19,554,943 | 19,224,069 |
accumulated other comprehensive gain | 50,000 | 50,000 | 17,000 | 27,000 | 34,000 | 82,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
accumulated deficit | -430,030,000 | -422,814,000 | -411,556,000 | -397,613,000 | -384,179,000 | -372,392,000 | -360,537,000 | -348,759,000 | -339,541,000 | -330,204,000 | -320,473,000 | -309,323,000 | -298,100,000 | -289,835,000 | -281,258,000 | -270,809,000 | -259,810,000 | -250,362,000 | -243,443,000 | -236,680,000 | -231,495,279 | -224,892,172 | -220,389,581 | -212,992,505 | -208,897,883 | -204,649,287 | -200,501,678 | -196,370,315 | -192,191,215 | -188,026,677 | -184,251,049 | -177,728,501 | -173,046,186 | -170,470,696 | -166,172,670 | -158,120,799 | -148,115,202 | -139,561,491 | -129,364,159 | -108,887,243 | ||||||||||||||
total stockholders’ equity | 45,388,000 | 48,790,000 | 58,606,000 | 70,876,000 | 82,949,000 | 49,392,000 | 52,388,000 | 60,894,000 | 69,739,000 | 77,827,000 | 86,579,000 | 96,503,000 | 106,343,000 | 113,212,000 | 120,474,000 | 130,102,000 | 140,417,000 | 133,544,000 | 138,918,000 | 124,817,000 | 128,157,882 | 33,522,550 | 24,384,039 | 6,143,418 | 7,311,344 | 6,655,980 | 8,848,235 | 9,686,181 | 10,084,192 | 13,979,755 | 17,477,162 | 4,679,090 | 6,506,107 | 3,944,872 | 3,510,769 | 10,680,488 | 19,768,139 | 26,774,399 | 32,572,874 | 48,701,289 | 18,118,940 | 23,562,675 | 8,349,553 | 12,353,756 | 17,329,335 | 17,752,767 | 20,392,000 | 21,138,154 | 1,535,667 | 2,169,028 | 4,975,392 | 5,489,301 | 25,079 | 1,365,116 |
total liabilities and stockholders’ equity | 61,884,000 | 63,780,000 | 75,739,000 | 84,807,000 | 97,190,000 | 62,896,000 | 66,051,000 | 74,038,000 | 81,637,000 | 88,452,000 | 97,455,000 | 106,549,000 | 116,191,000 | 123,631,000 | 131,261,000 | 139,204,000 | 149,544,000 | 141,312,000 | 143,734,000 | 129,573,000 | 134,727,387 | 39,450,449 | 30,128,979 | 11,815,403 | 13,086,546 | 11,922,463 | 13,867,963 | 14,533,200 | 14,172,496 | 17,920,822 | 21,768,042 | 10,408,519 | 12,284,941 | 12,217,903 | 12,560,754 | 33,925,069 | 43,950,411 | 53,003,670 | 56,722,912 | 71,445,651 | 43,643,796 | 45,832,315 | 28,896,846 | 32,762,283 | 36,193,484 | 27,155,735 | 29,150,565 | 644,937 | 2,004,991 | |||||
stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; 277 designated as series a convertible preferred stock; 61 shares outstanding at september 30, 2024 and december 31, 2023 with liquidation preference of 1,086 and 1,068 at september 30, 2024 and december 31, 2023, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; 277 designated as series a convertible preferred stock; 61 shares outstanding at june 30, 2024 and december 31, 2023 with liquidation preference of 1,080 and 1,068 at june 30, 2024 and december 31, 2023, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -97,000 | -132,000 | -67,000 | -407,000 | -431,000 | -76,000 | -395,000 | -779,000 | -982,000 | -748,000 | -142,000 | -10,000 | -67,000 | -15,194 | -13,650 | -13,626 | -10,773 | -4,742 | ||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; 277,100 designated as series a convertible preferred stock; 60,600 shares outstanding at march 31, 2024 and december 31, 2023 with liquidation preference of 1,074 and 1,068 at march 31, 2024 and december 31, 2023, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; 277,100 designated as series a convertible preferred stock; 60,600 shares outstanding at september 30, 2023 and december 31, 2022 with liquidation preference of 1,062 and 1,044 at september 30, 2023 and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; series a convertible preferred stock liquidation preference 1,056 and 1,044 at june 30, 2023 and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; series a convertible preferred stock liquidation preference 1,050 and 1,044 at march 31, 2023 and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other current liabilities | 8,000 | 10,000 | 42,000 | 42,000 | 42,000 | 42,000 | 42,000 | |||||||||||||||||||||||||||||||||||||||||||||||
service receivable | -139,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000 shares authorized; | 1,000 | 1,000 | 1,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
service receivables | -666,000 | -1,245,000 | -1,791,000 | -2,171,258 | -2,403,580 | -2,765,164 | -678,656 | -971,673 | -1,165,966 | -1,364,234 | -1,604,513 | |||||||||||||||||||||||||||||||||||||||||||
derivative financial instruments—warrants | 5,000 | 17,000 | 78,000 | 284,971 | 190,199 | 46,164 | 2,020 | 4,127 | 4,956 | 18,287 | 42,076 | 32,315 | 70,347 | 67,847 | 779,076 | 649,387 | 2,037,712 | 350,862 | 279,434 | 834,940 | ||||||||||||||||||||||||||||||||||
other liabilities | 30,000 | 214,000 | 191,000 | 156,266 | 88,452 | 72,701 | 139,044 | 128,368 | 1,519,109 | |||||||||||||||||||||||||||||||||||||||||||||
accrued expenses | 4,010,000 | 3,592,000 | 2,999,000 | 3,643,300 | 2,858,161 | 3,411,723 | 2,842,153 | 2,352,265 | 2,021,737 | 1,718,060 | 2,303,366 | 1,685,178 | 2,620,250 | 4,929,631 | 3,830,741 | 4,558,809 | 3,627,005 | 1,934,411 | 1,519,212 | 1,755,803 | 1,841,808 | 1,907,930 | 1,599,685 | 1,403,848 | 1,524,092 | 1,054,096 | 852,994 | 554,691 | 617,509 | 704,810 | ||||||||||||||||||||||||
accumulated other comprehensive income | 16,000 | 3,336 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | 2,055,321 | 713,913 | 845,845 | 956,616 | 946,388 | 877,853 | 789,285 | 508,408 | 418,040 | 369,259 | 348,018 | 295,755 | 262,188 | 152,789 | 129,393 | |||||||||||||||||||||||||||||||||||||||
note payable | 305,000 | 70,730 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 20,000,000 shares authorized; | 926 | 926 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
note payable, net of current portion | 234,270 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | 954,957 | 792,540 | 906,466 | 890,725 | 1,144,377 | 127,084 | 60,041 | 57,252 | 29,738 | 18,091 | ||||||||||||||||||||||||||||||||||||||||||||
deferred rent | 486,636 | 341,924 | 334,424 | 298,213 | 285,246 | 285,246 | 285,246 | 279,710 | ||||||||||||||||||||||||||||||||||||||||||||||
deferred rent, net of current portion | 1,090,671 | 1,204,109 | 1,004,689 | 1,096,591 | 1,183,677 | 1,153,316 | 1,236,941 | 1,307,598 | 1,373,717 | 1,446,912 | ||||||||||||||||||||||||||||||||||||||||||||
deferred rent, current portion | 472,251 | 349,565 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt | 1,174,989 | 1,331,515 | 1,488,041 | 1,644,567 | 3,873,438 | 2,360,109 | 801,024 | 6,146,744 | 5,225,818 | 2,320,084 | 3,064,734 | 1,898,548 | 752,734 | 200,792 | 198,166 | 147,618 | ||||||||||||||||||||||||||||||||||||||
short-term investment | 31,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | 77,095 | 178,127 | 157,445 | 80,348 | 100,460 | 85,152 | 158,537 | 98,736 | 99,717 | 59,391 | 56,694 | 62,370 | 59,910 | 129,303 | 78,994 | 69,566 | 58,064 | 168,381 | 128,188 | 106,027 | ||||||||||||||||||||||||||||||||||
long-term debt, less current portion | 12,699,739 | 14,176,359 | 15,595,400 | 9,031,389 | 11,246,188 | 12,881,673 | 12,011,645 | 13,053,117 | 13,978,818 | 14,702,866 | 274,852 | 322,998 | 370,431 | |||||||||||||||||||||||||||||||||||||||||
derivative financial instruments - warrants | 2,622,243 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
derivative financial instruments | 2,710,451 | 3,297,077 | 7,693,138 | 4,952,749 | 3,006,021 | 3,211,216 | 2,181,883 | 4,399,025 | 4,431,871 | 6,281,284 | 7,486,485 | 8,765,628 | 2,838,107 | 3,226,858 | 111,700 | 146,360 | ||||||||||||||||||||||||||||||||||||||
deficit accumulated during | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liability | 96,060 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
deficit accumulated during the development stage | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders’equity | 24,458,708 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
deficit accumulated during development stage | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash | 474,158 | 1,685,576 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
deposits | 55,698 | 55,698 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable and accrued expenses | 508,158 | 493,515 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred stock based compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
other asset |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss | -7,216,000 | -11,258,000 | -13,943,000 | -13,434,000 | -11,787,000 | -11,855,000 | -11,778,000 | -10,011,000 | -9,337,000 | -9,731,000 | -11,150,000 | -11,223,000 | -8,697,000 | -8,571,000 | -10,443,000 | -10,993,000 | -9,442,000 | -6,913,000 | -6,757,000 | -5,179,000 | -6,597,047 | -4,496,531 | -4,124,532 | -4,088,562 | -4,242,536 | -4,141,549 | -4,125,303 | -3,904,771 | -4,158,478 | -3,769,568 | -3,746,955 | -4,786,177 | -2,569,430 | -4,291,966 | -8,045,811 | -9,999,537 | -8,547,651 | -10,191,272 | -10,202,278 | -10,262,518 | -7,380,850 | -2,735,829 | -10,180,034 | -7,174,381 | -4,683,379 | -5,375,218 | -1,077,091 | -3,189,796 | -1,028,920 | -4,401,231 | -5,270,091 | -1,110,696 | -6,326,686 | -650,225 | -3,426,408 | -1,162,642 | ||
adjustments to reconcile net loss to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation | 88,000 | 89,000 | 94,000 | 93,000 | 96,000 | 101,000 | 105,000 | 102,000 | 103,000 | 107,000 | 98,000 | 90,000 | 86,000 | 81,000 | 38,000 | 31,000 | 113,000 | 110,000 | 109,000 | 119,000 | 117,261 | 114,839 | 8,181 | |||||||||||||||||||||||||||||||||||
stock-based compensation expense | 1,261,000 | 1,384,000 | 1,683,000 | 1,365,000 | 1,204,000 | 1,253,000 | 1,179,000 | 1,124,000 | 909,000 | 955,000 | 1,581,000 | 1,064,000 | 1,012,000 | 1,037,000 | 1,055,000 | 1,152,000 | 990,000 | 940,000 | 1,036,000 | 268,000 | 943,835 | 361,884 | 281,776 | 177,309 | 269,717 | 266,325 | ||||||||||||||||||||||||||||||||
amortization of right-of-use assets | 135,000 | 135,000 | 135,000 | 135,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accretion of discounts on short-term investments | -158,000 | -252,000 | -301,000 | -137,000 | -158,000 | -157,000 | -127,000 | -156,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable and unbilled receivable | 72,000 | 272,000 | -121,000 | 368,000 | -154,000 | -167,000 | -58,000 | -105,000 | -90,000 | -37,000 | 515,000 | 95,000 | -121,000 | -99,000 | -104,000 | 88,000 | -141,000 | -86,000 | -67,000 | 79,000 | -116,092 | -95,032 | -2,902 | 97,048 | -51,442 | -29,757 | ||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | -911,000 | 1,080,000 | 172,000 | 216,000 | -1,536,000 | 388,000 | 791,000 | -95,000 | -19,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
other assets | 0 | -148,000 | -144,000 | -188,000 | 1,198,000 | 4,000 | 4,000 | 4,000 | -29,000 | 26,000 | -1,203,000 | 1,000 | 3,000 | 51,000 | -95,000 | 120,000 | -25,000 | 166,000 | -248,462 | -3,185 | 3,785 | 1,206 | 13,367 | -35,681 | ||||||||||||||||||||||||||||||||||
accounts payable and accrued liabilities | 940,000 | -1,961,000 | 4,268,000 | -1,045,000 | 898,000 | -1,000 | 673,000 | 1,415,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
operating lease liabilities | -178,000 | -175,000 | -171,000 | -167,000 | -163,000 | -157,000 | -154,000 | -152,000 | -146,000 | -141,000 | -141,000 | -138,000 | -133,000 | -128,000 | -127,000 | -16,000 | -166,000 | -184,000 | -234,000 | -227,000 | -221,215 | -216,671 | -212,830 | -206,129 | -200,665 | -196,479 | ||||||||||||||||||||||||||||||||
net cash from operating activities | -5,967,000 | -10,834,000 | -8,328,000 | -12,794,000 | -10,267,000 | -10,456,000 | -9,230,000 | -7,740,000 | -7,139,000 | -7,957,000 | -7,132,000 | -8,659,000 | -9,390,000 | -7,486,000 | -6,695,000 | -10,249,000 | -7,390,000 | -5,465,000 | -4,301,000 | -5,884,000 | -5,123,937 | -3,525,238 | -4,291,150 | -3,374,637 | -3,276,864 | -3,187,477 | -3,443,113 | -3,360,046 | -3,612,780 | -3,479,479 | -3,250,607 | -2,856,147 | -3,331,415 | -6,594,318 | -4,597,126 | -8,758,208 | -9,004,857 | -7,041,570 | -8,077,721 | -6,915,707 | -6,808,936 | |||||||||||||||||
investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital expenditures | 0 | -18,000 | 0 | 0 | 0 | 0 | 0 | -80,000 | -8,000 | -315,000 | -251,000 | -8,000 | -75,000 | -448,000 | -312,000 | -171,000 | -107,000 | 0 | 0 | 0 | -58,096 | 0 | 0 | 0 | 0 | -62,348 | 0 | -5,274 | 0 | 0 | 0 | -5,100 | 35,150 | -115,513 | -9,286 | -11,452 | -25,702 | -126,914 | -318,844 | -352,023 | -984,078 | |||||||||||||||||
free cash flows | -5,967,000 | -10,852,000 | -8,328,000 | -12,794,000 | -10,267,000 | -10,456,000 | -9,230,000 | -7,820,000 | -7,147,000 | -8,272,000 | -7,383,000 | -8,667,000 | -9,465,000 | -7,934,000 | -7,007,000 | -10,420,000 | -7,497,000 | -5,465,000 | -4,301,000 | -5,884,000 | -5,182,033 | -3,525,238 | -4,291,150 | -3,374,637 | -3,276,864 | -3,249,825 | -3,443,113 | -3,365,320 | -3,612,780 | -3,479,479 | -3,250,607 | -2,861,247 | -3,296,265 | -6,709,831 | -4,606,412 | -8,769,660 | -9,030,559 | -7,168,484 | -8,396,565 | -7,267,730 | -7,793,014 | |||||||||||||||||
maturities of short-term investments | 16,572,000 | 19,519,000 | 13,792,000 | 21,228,000 | 4,511,000 | 10,090,000 | 6,870,000 | 5,635,000 | 6,018,000 | 12,269,000 | 25,282,000 | 42,983,000 | 15,216,000 | 12,428,000 | 10,584,000 | 38,217,000 | 13,290,000 | 9,591,000 | 0 | 0 | 2,431,837 | 14,000,000 | ||||||||||||||||||||||||||||||||||||
purchases of short-term investments | -6,722,000 | -9,341,000 | -19,985,000 | -35,812,000 | 0 | -22,644,000 | 0 | -919,000 | -2,593,000 | -16,623,000 | -13,541,000 | -37,327,000 | -10,805,000 | -23,119,000 | -20,536,000 | -36,773,000 | -27,753,000 | -4,684,000 | -27,753,000 | -114,195,000 | 0 | 0 | 0 | 0 | 0 | -8,804,604 | ||||||||||||||||||||||||||||||||
sales of short-term investments | 899,000 | 0 | 0 | 3,120,000 | 10,144,000 | 8,490,000 | -6,000 | 1,681,000 | 2,684,000 | 16,259,000 | 17,801,000 | 17,085,000 | 5,776,000 | 3,240,000 | 3,238,000 | 2,497,000 | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||
net cash from investing activities | 10,749,000 | 10,160,000 | -4,983,000 | -14,584,000 | 4,511,000 | -9,434,000 | 14,015,000 | 4,636,000 | 13,561,000 | 3,821,000 | 11,484,000 | 7,329,000 | 7,020,000 | 5,163,000 | 7,608,000 | 18,358,000 | -8,794,000 | 8,049,000 | -19,005,000 | -111,698,000 | -58,096 | -62,348 | 0 | -5,274 | 0 | 59,442 | -31,500 | -5,100 | 36,690 | -115,513 | 18,857,104 | 5,183,944 | 415,743 | 3,373,086 | -28,270,455 | -352,023 | -976,478 | |||||||||||||||||||||
financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 0 and 3,286, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants, net of expense of 169 and 0, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of options | 465,000 | 25,000 | 0 | 3,000 | 13,000 | 0 | 253,000 | 107,000 | 0 | 141,364 | 0 | 134,822 | 98,531 | 133,613 | 42,601 | 254,200 | 328,013 | 236,038 | ||||||||||||||||||||||||||||||||||||||||
net cash from financing activities | 2,553,000 | 25,000 | 0 | 3,000 | 44,188,000 | 7,427,000 | 2,058,000 | 107,000 | 0 | 14,962,000 | 0 | 19,225,000 | 1,263,000 | 99,757,282 | 12,329,641 | 22,768,938 | 2,456,370 | 4,439,950 | 1,490,761 | 2,904,304 | 3,242,266 | 0 | 0 | 15,110,899 | 1,292,641 | 4,069,785 | 6,371,486 | -16,662,802 | -156,526 | -60,618 | 3,657,682 | -1,059,734 | -235,954 | 1,128,664 | 21,681,823 | 61,277 | 0 | -29,495 | 21,805,911 | 1,140,767 | 66,505 | 4,378,033 | -490 | 10,057,105 | 889,500 | |||||||||||||
net change in cash and cash equivalents | 7,335,000 | -649,000 | -13,311,000 | -27,375,000 | 38,432,000 | -12,463,000 | 6,843,000 | -2,997,000 | 6,422,000 | -4,136,000 | 4,352,000 | -1,330,000 | -2,370,000 | -2,248,000 | 913,000 | 8,109,000 | -1,222,000 | 2,584,000 | -4,081,000 | -116,319,000 | 94,575,249 | 8,650,619 | 18,477,788 | -918,267 | 1,163,086 | -1,759,064 | -538,809 | -123,054 | -3,612,780 | -3,420,037 | ||||||||||||||||||||||||||||
cash and cash equivalents—beginning of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents—end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplementary disclosure of cash flow activity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of non-cash investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for taxes | 1,000 | 0 | 0 | 1,000 | 0 | 0 | 0 | 1,000 | 0 | 0 | 0 | 800 | 0 | 0 | 0 | 800 | 0 | 0 | 0 | 0 | 0 | 0 | 16,134 | 0 | 0 | 800 | 0 | 0 | 0 | 2,400 | ||||||||||||||||||||||||||||
purchases of unsettled short-term investments included in accrued liabilities | 902,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 0 and 482, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents—beginning of period | 0 | 0 | 51,470,000 | 0 | 0 | 0 | 21,655,000 | 0 | 0 | 0 | 16,347,000 | 0 | 0 | 0 | 11,943,000 | 0 | 0 | 0 | 130,981,000 | 0 | 0 | 0 | 10,195,292 | 0 | 0 | 0 | 11,453,133 | 0 | 0 | 0 | 8,225,764 | 0 | 0 | 0 | 13,915,094 | 0 | 0 | 0 | 67,493,047 | 0 | 0 | 0 | 27,293,798 | 0 | 0 | 0 | 25,836,937 | 0 | 0 | 0 | 10,819,781 | 0 | 0 | 0 | 700,374 | |||
cash and cash equivalents—end of period | -649,000 | -13,311,000 | 24,095,000 | 38,432,000 | -12,463,000 | 6,843,000 | 18,658,000 | 6,422,000 | -4,136,000 | 4,352,000 | 15,017,000 | -2,370,000 | -2,248,000 | 913,000 | 20,052,000 | -1,222,000 | 2,584,000 | -4,081,000 | 14,662,000 | 94,575,249 | 8,650,619 | 18,477,788 | 9,277,025 | 1,163,086 | -1,759,064 | -538,809 | 11,330,079 | -3,612,780 | -3,420,037 | 11,828,792 | 6,657,158 | 791,466 | -349,593 | -2,399,569 | 10,183,460 | -8,654,013 | -9,873 | -37,410,349 | 59,989,329 | -6,656,750 | 32,856,013 | -2,701,858 | 43,995,642 | -3,869,761 | -3,510,334 | 11,802,771 | 22,871,122 | -1,962,450 | 19,497,097 | -861,985 | 9,164,275 | 3,004,653 | -1,489,282 | 8,717,633 | 586,777 | |||
proceeds from sales of common stock, net of expenses of 0 and 197, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of property and equipment included in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating lease right-of-use assets | 135,000 | 135,000 | 135,000 | 134,000 | 135,000 | 135,000 | 137,000 | 136,000 | 137,000 | 136,000 | 136,000 | 136,000 | 221,000 | 221,000 | 83,000 | 82,000 | 80,162 | 78,731 | 81,559 | 79,796 | -164,518 | 157,296 | ||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 3,286 and 0, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 482 and 0, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 197 and 0, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure of non-cash investing and financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of property and equipment included in accounts payable and accrued expenses | -117,000 | 133,000 | -201,000 | 429,000 | 27,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of assets | 0 | 0 | 0 | 1,000 | 165,459 | -609 | 426,852 | 102 | ||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of (discounts) and premiums on short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
release of clinical trial funding commitment | 0 | 0 | 0 | 139,000 | 527,000 | 579,000 | 546,000 | 380,000 | 232,322 | 361,584 | 213,492 | 293,017 | 194,293 | 198,268 | 240,279 | 70,487 | ||||||||||||||||||||||||||||||||||||||||||
accounts payable and accrued expenses | 1,403,000 | 135,000 | 1,090,000 | 203,000 | 23,000 | -42,000 | 1,549,000 | 291,000 | 300,000 | -1,421,000 | 957,175 | 833,230 | -602,522 | 88,283 | 617,785 | 450,505 | ||||||||||||||||||||||||||||||||||||||||||
other liabilities | -8,000 | -2,000 | 10,000 | -42,000 | -30,000 | -184,000 | 24,000 | 34,000 | 109,814 | 15,751 | -66,343 | 10,676 | ||||||||||||||||||||||||||||||||||||||||||||||
insurance proceeds from casualty loss | 0 | 43,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative preferred stock dividend adjustment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of premiums on short-term investments | -311,000 | -242,000 | -163,000 | -40,000 | 115,000 | 211,000 | 346,000 | 447,000 | 462,000 | 494,000 | 204,000 | 0 | 0 | -1,647 | 10,877 | 45,542 | 34,238 | |||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | 1,009,000 | 1,251,000 | -14,000 | 1,159,000 | -1,141,000 | -809,000 | 251,000 | -183,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of property and equipment included in insurance proceeds receivable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative financial instruments—warrants | -5,000 | -12,000 | -61,000 | -207,000 | 94,772 | 144,035 | 44,144 | -2,107 | -829 | -13,331 | -23,789 | 9,761 | -38,032 | 2,500 | -711,229 | 129,689 | -1,388,325 | -1,528,669 | 71,428 | -555,506 | ||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock, preferred stock and warrants, net of expenses of 0 and 813 respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants | 0 | 0 | 0 | 1,263,000 | 5,899,398 | 1,456,369 | 8,499 | 7,180 | 1,564 | 3,282,266 | 0 | 0 | 163,500 | 1,449,167 | 0 | 904,400 | 0 | 2,707,727 | 825,599 | 66,505 | ||||||||||||||||||||||||||||||||||||||
accretion of series a convertible preferred stock dividend | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses of 0 and 776, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock dividend payable on series a convertible preferred stock | 6,000 | 6,000 | 6,000 | 6,000 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | ||||||||||||||||||||||||||||||||||||||||||||||
impairment loss | 0 | 0 | 0 | 0 | 104,700 | 0 | 0 | 485,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock, preferred stock and warrants, net of expenses of 813 and 7,507 respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
costs related to the clinical trial funding commitment | 0 | 0 | 0 | 0 | 0 | -40,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under note payable | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of note payable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, preferred stock and warrants, net of expenses of 776 and 634, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, preferred stock and warrants, net of expenses of 776 and 93, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, preferred stock and warrants, net of expenses of 0 and 634, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock, preferred stock and warrants, net of expenses of 7,507,123 and 158,678 respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized for beneficial conversion features of series c convertible preferred stock issuance | 268,269 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized for beneficial conversion features of series d convertible preferred stock issuance | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized for beneficial conversion features of series e convertible preferred stock issuance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock, series c convertible preferred stock and warrants issued in connection with clinical trial funding commitment, net of discount of 235,640 | 1,675,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses | -623,873 | -55,535 | 55,506 | -162,417 | 113,926 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, preferred stock and warrants, net of expenses of 633,807 and 97,260, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, preferred stock and warrants, net of expenses of 92,648 and 97,260, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of warrants, net of expenses of 393,285 and 0, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under long-term debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
expenses from sales of common stock, preferred stock and warrants included in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
expenses from exercise of warrants included in accounts payable and accrued liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 119,320 | 364,013 | 43,000 | 41,308 | 45,911 | 157,713 | 218,279 | 231,015 | 252,480 | 290,581 | 311,033 | 314,994 | 330,968 | 376,062 | 203,777 | 332,887 | 156,821 | 128,111 | 97,621 | 84,460 | 68,519 | 65,214 | 58,299 | 57,772 | 53,528 | 44,988 | 41,599 | 26,154 | 17,779 | 11,511 | 12,356 | 7,785 | 6,190 | |||||||||||||||||||||||||
proceeds from sales of common stock and warrants | 1,000,001 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on extinguishment of debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred rent | 325,762 | -102,709 | -84,261 | -79,586 | 66,572 | -70,659 | -70,657 | -66,119 | -67,659 | -66,689 | ||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from disposals of capital equipment | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided (used) by investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock and warrants, net of expenses of 158,678 and 1,336,123 respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of series b convertible preferred stock, net of expenses of 0 and 497,617 respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments under equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment upon debt extinguishment | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for interest | 0 | 0 | 6,065 | 16,417 | 18,134 | 20,379 | 329,912 | 300,040 | 297,449 | 269,501 | 260,513 | 276,214 | 266,618 | 265,125 | 265,125 | 265,125 | 176,750 | 176,750 | 65,155 | 6,601 | ||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock and warrants, net of expenses of 113,678 and 1,336,123, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of series b convertible preferred stock, net of expenses of 497,617 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of equipment line of credit | 0 | -1,043,507 | -156,526 | -156,526 | -156,526 | -156,526 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock and warrants, net of expenses of 97,260 and 1,336,123, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock based compensation expense | 200,067 | 278,221 | 221,300 | 1,406,131 | 1,421,180 | 775,385 | 920,799 | 1,829,371 | 1,301,913 | 2,811,108 | 923,660 | 1,123,446 | 711,741 | 685,235 | 405,699 | 419,487 | 559,773 | 122,680 | 969,076 | 347,342 | 540,266 | 183,130 | 130,360 | 115,820 | 102,830 | -687,703 | 187,523 | |||||||||||||||||||||||||||||||
decrease in other assets | 15,725 | 0 | 0 | 2,761 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in accounts receivable and unbilled receivable | 52,079 | -39,178 | -4,495 | -9,739 | 72,674 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in prepaid expenses and other current assets | 179,691 | 125,425 | 93,637 | 97,684 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in operating lease right-of-use assets | 154,058 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable and accrued expenses | 3,635 | -146,553 | -255,664 | 587,743 | 50,958 | -1,032,203 | -2,189,316 | 641,097 | -360,577 | -332,916 | 1,008,605 | 409,189 | 1,072,343 | -254,934 | 588,132 | 138,126 | 14,479 | 313,226 | 316,554 | |||||||||||||||||||||||||||||||||||||||
decrease in operating lease liabilities | -186,689 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | 0 | 0 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
accretion of final fee premium | 0 | 0 | 168,602 | 125,012 | 124,125 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of discount on debt | 0 | 0 | 45,557 | 68,223 | 68,093 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
net realized loss on short-term investments | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest income accrued on short-term investments | 0 | 0 | -241,913 | 151,583 | -94,304 | 85,422 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in other assets | 146,847 | 29,141 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in prepaid expenses | 132,614 | 110,957 | 12,703 | 217 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock and warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of series b convertible preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of stock issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of long-term debt | 0 | 0 | 0 | -6,576,083 | -1,400,219 | -919,864 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash and cash equivalents | 16,406 | -11,248 | 3,255 | -844 | -4,281 | 929 | -2,439 | -34 | ||||||||||||||||||||||||||||||||||||||||||||||||||
deemed dividend recognized for beneficial conversion features of series b convertible preferred stock issuance | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock issued upon conversion of series b convertible preferred stock | 0 | 565 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock and warrants, net of expenses of 1,336,123 and 575,516, respectively | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock and warrants, net of expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of series b convertible preferred stock, net of expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in cash and equivalents | -1,568,606 | -349,593 | -2,399,569 | -3,731,634 | -9,873 | -37,410,349 | -7,503,718 | 32,856,013 | -2,701,858 | 16,701,844 | -3,510,334 | |||||||||||||||||||||||||||||||||||||||||||||||
preferred stock dividends accrued | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 6,060 | 1,685 | 9,210 | |||||||||||||||||||||||||||||||||||||||||
decrease in accounts receivable | 101,032 | 20,112 | -15,308 | 36,801 | 189,630 | 5,676 | -2,460 | -9,428 | -13,065 | 1,563 | 110,317 | 22,607 | ||||||||||||||||||||||||||||||||||||||||||||||
increase in prepaid expenses and other current assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under equipment line of credit | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from borrowings under long-term debt, net of costs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants issued in connection with long-term debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
leasehold improvements paid for by lessor | 0 | 0 | 0 | 1,860,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under long-term debt, net of costs | -1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts receivable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sales of common stock, net of expenses | 37,399,106 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in other liabilities | -268,694 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in prepaid expenses | -120,276 | -68,373 | -37,406 | -51,272 | -393,788 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock, net of expenses | -67,744 | 4,377,433 | -490 | 10,057,105 | 889,500 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
reclassification of derivative financial instruments to additional paid-in capital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net gain on disposal of fixed assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative financial instruments - warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net purchases of short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants issued in connection with amendment to the loan and security agreement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
reclassification of derivative financial instruments - warrants to additional paid in capital | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt costs | 88,256 | 93,062 | 93,129 | 59,962 | 68,353 | 124,713 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
accretion of discount on debt | 25,010 | 27,631 | 28,458 | 2,639 | 28,540 | 28,486 | 28,431 | |||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of derivative instruments - warrants | -52,876 | -533,750 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
reclassification of derivative financial instruments to additional paid in capital | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowing under equipment line of credit | 550,297 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of fixed assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of financial instruments | -1,849,413 | 1,317,359 | 4,896,240 | -388,750 | 2,180,891 | 32,424 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
stock and warrant issued in connection with consulting services | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under debt agreement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
warrants issued in connection with loan and security agreement | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net loss on disposal of fixed assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss from the change in fair value of derivative instruments - warrants | -4,017,212 | 3,175,754 | 1,946,728 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
net borrowings under debt agreements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net repayments from equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) decrease in accounts receivable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by financing activities | 115,806 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of fixed assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital expenditures, net of proceeds from disposals | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds of sale of common stock, net of expenses | 21,445,785 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
repayments of debt outstanding under equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings (repayments) under equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of 125,000 shares of common stock pursuant to asset purchase agreement with multigen diagnostics, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
correction of error in derivative financial instruments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
non-cash interest expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable,accrued expenses and other long-term liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under debt agreement, net of expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (repayments) borrowings from equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
founders compensation contributed to equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
donated services contributed to equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
settlement of consulting services in stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of deferred debt costs and original issue discount | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liquidated damages and other forbearance agreement settlement costs paid in stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest expense on convertible debentures paid in stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchased in process research and development expense-related party | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock issued in connection with payment of deferred salary | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock issued in connection with settlement of legal fees | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets acquired in etherogen, inc. merger | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of 6% convertible debenture | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
debt issuance costs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from a non-exclusive selling agent’s agreement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net borrowings (repayments) under equipment line of credit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
costs associated with recapitalization | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of finders’ fee on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
redemption of common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of preferred stock dividends | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in cash and equivalent | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of 41,750 shares of common stock for prior year board of directors’ fees in lieu of cash payment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
conversion of 2,335,050 of 6% debentures | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of 2,043,797 shares of common stock pursuant to agreement and plan of merger with etherogen, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
series a preferred beneficial conversion feature accreted as a dividend | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock from net exercise of warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
interest paid in common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
founders’, compensation contributed to equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in accounts payable, accrued expenses and other | 93,286 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings under capital lease line | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock issued in connection with consulting services | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
borrowings on capital lease obligations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of stock options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in cash and equivalent-increase | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock and warrants issued in connection with consulting services | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from exercise of options to purchase common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
note | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of finders’_fee on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase (decrease) in fair value of derivative financial instruments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of warrants for services | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
write-off of abandoned leasehold improvement project | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) decrease in prepaid expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) decrease in other assets | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase (decrease) in accounts payable and accrued expenses | 14,643 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of property and equipment and additions to construction-in-progress | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of common stock net of expenses | 129,060 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of acquisition costs on common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of preferred stock net of expenses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment of acquisition costs on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in cash | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash - beginning of period | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash - end of period | -1,211,418 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
conversion of 144,058 shares of preferred stock into 670,036 shares of common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase (decrease) in fair value of derivative financial instrument | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization of purchase discount on marketable securities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(increase) decrease in receivables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of marketable investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by investing activities |